These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36053771)

  • 1. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
    Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R
    J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2-Positive Breast Cancer and Other Solid Tumors.
    Yin O; Xiong Y; Endo S; Yoshihara K; Garimella T; AbuTarif M; Wada R; LaCreta F
    Clin Pharmacol Ther; 2021 May; 109(5):1314-1325. PubMed ID: 33118153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
    Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
    Oliveira M; Falato C; Cejalvo JM; Vila MM; Tolosa P; Salvador-Bofill FJ; Cruz J; Arumi M; Luna AM; Guerra JA; Vidal M; Martínez-Sáez O; Paré L; González-Farré B; Sanfeliu E; Ciruelos E; Espinosa-Bravo M; Pernas S; Izarzugaza Y; Esker S; Fan PD; Parul P; Santhanagopal A; Sellami D; Villacampa G; Ferrero-Cafiero JM; Pascual T; Prat A
    Ann Oncol; 2023 Aug; 34(8):670-680. PubMed ID: 37211044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
    Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
    J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.
    Nagai Y; Oitate M; Shiozawa H; Ando O
    Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
    Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA
    J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
    Koyama K; Ishikawa H; Abe M; Shiose Y; Ueno S; Qiu Y; Nakamaru K; Murakami M
    PLoS One; 2022; 17(5):e0267027. PubMed ID: 35503762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
    Jänne PA; Baik C; Su WC; Johnson ML; Hayashi H; Nishio M; Kim DW; Koczywas M; Gold KA; Steuer CE; Murakami H; Yang JC; Kim SW; Vigliotti M; Shi R; Qi Z; Qiu Y; Zhao L; Sternberg D; Yu C; Yu HA
    Cancer Discov; 2022 Jan; 12(1):74-89. PubMed ID: 34548309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice.
    Okamoto H; Oitate M; Hagihara K; Shiozawa H; Furuta Y; Ogitani Y; Kuga H
    Xenobiotica; 2020 Oct; 50(10):1242-1250. PubMed ID: 32306807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
    Yin O; Iwata H; Lin CC; Tamura K; Watanabe J; Wada R; Kastrissios H; AbuTarif M; Garimella T; Lee C; Zhang L; Shahidi J; LaCreta F
    Clin Pharmacol Ther; 2021 Oct; 110(4):986-996. PubMed ID: 33999422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
    Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
    Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
    Takahashi S; Karayama M; Takahashi M; Watanabe J; Minami H; Yamamoto N; Kinoshita I; Lin CC; Im YH; Achiwa I; Kamiyama E; Okuda Y; Lee C; Bang YJ
    Clin Cancer Res; 2021 Nov; 27(21):5771-5780. PubMed ID: 34426442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
    Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F
    J Clin Oncol; 2024 Jul; 42(19):2281-2294. PubMed ID: 38652877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
    Brasó-Maristany F; Ferrero-Cafiero JM; Falato C; Martínez-Sáez O; Cejalvo JM; Margelí M; Tolosa P; Salvador-Bofill FJ; Cruz J; González-Farré B; Sanfeliu E; Òdena A; Serra V; Pardo F; Luna Barrera AM; Arumi M; Guerra JA; Villacampa G; Sánchez-Bayona R; Ciruelos E; Espinosa-Bravo M; Izarzugaza Y; Galván P; Matito J; Pernas S; Vidal M; Santhanagopal A; Sellami D; Esker S; Fan PD; Suto F; Vivancos A; Pascual T; Prat A; Oliveira M
    Nat Commun; 2024 Jul; 15(1):5826. PubMed ID: 38992028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression.
    Vasalou C; Proia TA; Kazlauskas L; Przybyla A; Sung M; Mamidi S; Maratea K; Griffin M; Sargeant R; Urosevic J; Rosenbaum AI; Yuan J; Aluri KC; Ramsden D; Hariparsad N; Jones RDO; Mettetal JT
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):994-1005. PubMed ID: 38532525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
    Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
    Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.